Paid Clinical Trials Hattiesburg
Discover 42 paid clinical trials in Hattiesburg, Mississippi. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid ArthritisStudy to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Sponsor:
AbbVie
Location:
Code:
NCT05814627
Conditions
Rheumatoid Arthritis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Upadacitinib
Adalimumab
Upadacitinib Matching Placebo
Adalimumab Matching Placebo
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaStudy of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Sponsor:
Arcus Biosciences, Inc.
Location:
Code:
NCT06608927
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Quemliclustat
Placebo
Nab-paclitaxel
Gemcitabine
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast CancerA Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Sponsor:
AstraZeneca
Location:
Code:
NCT06103864
Conditions
Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Dato-DXd
Durvalumab
Paclitaxel
Nab-paclitaxel
Gemcitabine
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationA Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
Sponsor:
Novo Nordisk A/S
Location:
Code:
NCT05636176
Conditions
Heart Failure
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Ziltivekimab
Placebo
MILD® Percutaneous Image-Guided Lumbar Decompression: a Medicare Claims StudyMILD® Percutaneous Image-Guided Lumbar Decompression: a Medicare Claims Study
Sponsor:
Vertos Medical, Inc.
Location:
Code:
NCT03072927
Conditions
Lumbar Spinal Stenosis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
MILD
Interspinous Process Decompression
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study, CA-0011)A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study, CA-0011)
Sponsor:
Cognito Therapeutics, Inc.
Location:
Code:
NCT05637801
Conditions
Alzheimer Disease
Alzheimer Disease 1
Alzheimer Disease 2
Alzheimer Disease 3
Alzheimer Disease, Early Onset
Eligibility Criteria
Sex: All
Age: 50 - 70+
Healthy Volunteers: Not accepted
Interventions
Sensory Stimulation System (GS120) - Active
Sensory Stimulation System (GS120) - Sham
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell LymphomaA Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma
Sponsor:
BeiGene
Location:
Code:
NCT06742996
Conditions
Mantle Cell Lymphoma
B Cell Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Sonrotoclax
Zanubrutinib
Placebo
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal CancerA Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Sponsor:
Janssen Research & Development, LLC
Location:
Code:
NCT06662786
Conditions
Colorectal Neoplasms
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Amivantamab
Cetuximab
5-fluorouracil
Leucovorin calcium/Levoleucovorin
Oxaliplatin
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLCTo Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Sponsor:
Shanghai Henlius Biotech
Location:
Code:
NCT05468489
Conditions
Extensive Stage Small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Serplulimab + chemotherapy (carboplatin-etoposide)
Atezolizumab + chemotherapy (carboplatin-etoposide)
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and ObesityA Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
Sponsor:
University of Southern Mississippi
Location:
Code:
NCT05997862
Conditions
Osteoarthritis, Knee
Obesity
Eligibility Criteria
Sex: All
Age: 30 - 70+
Healthy Volunteers: Not accepted
Interventions
HFFS